Washington, DC (UroToday.com) Gordon Robertson from British Columbia Cancer Agency, Genome Sciences Centre discussed his experience with the development of The Cancer Genome Atlas (TCGA) and the PanCancer Atlas as well and the Genome Data Commons’ (GDC). He further opened the discussion presenting the recent work on the Consensus Classification system as an example of team science […]
The aim of the present study was to construct a novel classification based on perioperative changes of membranous urethral length (MUL) using hierarchical cluster analysis to predict urinary incontinence (UI) and overactive bladder (OAB) symptoms after robot-assisted radical prostatectomy (RARP).
The aim of the present study was to construct a novel classification based on perioperative changes of membranous urethral length (MUL) using hierarchical cluster analysis to predict urinary incontinence (UI) and overactive bladder (OAB) symptoms after robot-assisted radical prostatectomy (RARP).
The current status of robot-assisted radical cystectomy was reviewed 16 years after the initial robot-assisted radical cystectomy for the treatment of invasive bladder cancer. Articles associated with robot-assisted radical cystectomy and written in English were selected from the PubMed database from January 2003 to February 2019.
Washington, DC (UroToday.com) Nikolaus Schultz from Memorial Sloan Kettering discussed the MSK IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets). While this is promising work towards precision-based medicine he mentioned most mutations identified are passenger mutations which are not relevant but ‘along for the ride’. However, IMPACT can infer tumor mutational burden to identify the driver […]
Washington, DC (UroToday.com) Seungchan Kim from Praire View A&M University discussed biomarker discovery. He reviewed the importance of sample size, bioprocessing, and internal validation. First, you have to determine the hypothesis and sufficient power needed to test the hypothesis. Normalization compensates for technical and/or biological covariates ie RNA seq. which can be single sample or […]
Washington, DC (UroToday.com) Seungchan Kim from Praire View A&M University discussed biomarker discovery. He reviewed the importance of sample size, bioprocessing, and internal validation. First, you have to determine a hypothesis and the sufficient power needed to test the hypothesis. Normalization compensates for technical and/or biological covariates ie RNA seq. which can be single sample or […]
Washington, DC (UroToday.com) The expert panel of providers and FDA discussed ongoing and future collaborations with the FDA and bladder cancer. The FDA Oncology Center of Excellence (OCE) leverages the combined skills of regulatory scientists and reviewers. The panel reviewed the structure of the OCE and how expedited programs within the FDA strive to accelerate […]
Washington, DC (UroToday.com) During the Bladder Cancer Award Ceremony, Seth Lerner from Baylor College of Medicine, presented his summary of his 2017 BCAN Innovation Award. He initially discussed the premise of his work in terms of alternative treatment options including immunotherapy, chemotherapy/immunotherapy, and targeted therapy. The study hypothesis was an integrated analysis of proteomics and […]
Washington, DC (UroToday.com) Samuel Washington, MD from the University of California San Francisco, San Francisco, CA discussed race and guideline based treatment of bladder cancer. Access to care and socioeconomic status are known predictors for this disparity. They used the NCDB to determine how race impacted treatment received and survival. A total of 51,380 patients […]
